1 Article found

Zymeworks Inc articles

Zanidatamab, a HER2-targeted bispecific antibody, in combination with docetaxel as first-line therapy for patients with advanced HER2-positive breast cancer: Preliminary results from a Phase 1b/2 study (American Society of Clinical Oncology)

Worldwide, breast cancer is the most commonly diagnosed cancer and the

Jun. 0, 2022